Literature DB >> 28951071

Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Mugdha V Rairikar1, Laura E Case2, Lauren A Bailey1, Zoheb B Kazi1, Ankit K Desai1, Kathryn L Berrier1, Julie Coats3, Rachel Gandy3, Rebecca Quinones3, Priya S Kishnani4.   

Abstract

OBJECTIVE: Newborn screening (NBS) has led to early diagnosis and early initiation of treatment for infantile onset Pompe Disease (IOPD). However, guidelines for management of late onset Pompe disease (LOPD) via NBS, especially with the IVS c.-32-13T>G are not clear. This IVS variant is noted in 68-90% cases with LOPD and has been presumed to result in "adult" disease in compound heterozygosity, with a few cases with earlier onset and a mild to no phenotype in homozygosity. Our study evaluates newborns with LOPD having IVS variant with a diligent multidisciplinary approach to determine if they have an early presentation.
METHODS: Seven children with LOPD identified by NBS with IVS variant (3 compound heterozygous, and 4 homozygous) were evaluated with clinical, biochemical (CK, AST, ALT, and urinary Glc4), cardiac evaluation, physical therapy (PT), occupational, and speech/language therapy.
RESULTS: All seven patients demonstrated motor involvement by age 6months; the three patients with c.-32-13 T>G variant in compound heterozygosity had symptoms as neonates. Patients with c.-32-13 T>G variant in compound heterozygosity had more involvement with persistent hyperCKemia, elevated AST and ALT, swallowing difficulties, limb-girdle weakness, delayed motor milestones, and were initiated on ERT. The patients with c.-32-13T>G variant in homozygosity had normal laboratory parameters, and presented with very subtle yet LOPD specific signs, identified only by meticulous assessments.
CONCLUSION: This patient cohort represents the first carefully phenotyped cohort of infants with LOPD with the "late-onset" GAA variant c.-32-13T>G detected by NBS in the USA. It emphasizes not only the opportunity for early detection of skeletal and other muscle involvement in infants with c.-32-13T>G variant but also a high probability of overlooking or underestimating the significance of clinically present and detectable features. It can thus serve as a valuable contribution in the development of evaluation and treatment algorithms for infants with LOPD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enzyme replacement therapy; Glycogen storage disease type II; IVS variant; Late onset Pompe disease; Newborn screening; c.-32-13T>G

Mesh:

Substances:

Year:  2017        PMID: 28951071      PMCID: PMC5722675          DOI: 10.1016/j.ymgme.2017.09.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  44 in total

1.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Authors:  S Strothotte; N Strigl-Pill; B Grunert; C Kornblum; K Eger; C Wessig; M Deschauer; F Breunig; F X Glocker; S Vielhaber; A Brejova; M Hilz; K Reiners; W Müller-Felber; E Mengel; M Spranger; Benedikt Schoser
Journal:  J Neurol       Date:  2009-08-01       Impact factor: 4.849

2.  Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.

Authors:  M A Kroos; R J Pomponio; M L Hagemans; J L M Keulemans; M Phipps; M DeRiso; R E Palmer; M G E M Ausems; N A M E Van der Beek; O P Van Diggelen; D J J Halley; A T Van der Ploeg; A J J Reuser
Journal:  Neurology       Date:  2007-01-09       Impact factor: 9.910

Review 3.  Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.

Authors:  Nina Raben; Amanda Wong; Evelyn Ralston; Rachel Myerowitz
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

4.  Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

Authors:  Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

5.  Pompe disease in infants: improving the prognosis by newborn screening and early treatment.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Beth L Thurberg; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ai-Chu Huang; Mei-Hwan Wu; Pei-Hsin Huang; Fuu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

6.  Assessment of gross motor skills of at-risk infants: predictive validity of the Alberta Infant Motor Scale.

Authors:  J Darrah; M Piper; M J Watt
Journal:  Dev Med Child Neurol       Date:  1998-07       Impact factor: 5.449

Review 7.  Pompe disease: early diagnosis and early treatment make a difference.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu; Ni-Chung Lee
Journal:  Pediatr Neonatol       Date:  2013-04-28       Impact factor: 2.083

8.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.

Authors:  A L E Montalvo; B Bembi; M Donnarumma; M Filocamo; G Parenti; M Rossi; L Merlini; E Buratti; P De Filippi; A Dardis; M Stroppiano; G Ciana; M G Pittis
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

Review 9.  Physical therapy management of Pompe disease.

Authors:  Laura Elizabeth Case; Priya Sunil Kishnani
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

10.  A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.

Authors:  Andreas Herzog; Ralf Hartung; Arnold J J Reuser; Pia Hermanns; Heiko Runz; Nesrin Karabul; Seyfullah Gökce; Joachim Pohlenz; Christoph Kampmann; Christina Lampe; Michael Beck; Eugen Mengel
Journal:  Orphanet J Rare Dis       Date:  2012-06-07       Impact factor: 4.123

View more
  12 in total

Review 1.  Gene therapy for glycogen storage diseases.

Authors:  Priya S Kishnani; Baodong Sun; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

Review 4.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

5.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

6.  Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.

Authors:  Mrudu Herbert; Laura E Case; Mugdha Rairikar; Heidi Cope; Lauren Bailey; Stephanie L Austin; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2018-08-23       Impact factor: 4.204

7.  Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.

Authors:  Monique Piraud; Magali Pettazzoni; Marie de Antonio; Christine Vianey-Saban; Roseline Froissart; Brigitte Chabrol; Sarah Young; Pascal Laforêt
Journal:  Mol Genet Metab Rep       Date:  2020-05-01

8.  A Newborn Screening, Presymptomatically Identified Infant With Late-Onset Pompe Disease: Case Report, Parental Experience, and Recommendations.

Authors:  Raymond Y Wang
Journal:  Int J Neonatal Screen       Date:  2020-03-14

Review 9.  Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.

Authors:  Naresh K Meena; Nina Raben
Journal:  Biomolecules       Date:  2020-09-18

10.  Newborn Screening for Pompe Disease: Pennsylvania Experience.

Authors:  Can Ficicioglu; Rebecca C Ahrens-Nicklas; Joshua Barch; Sanmati R Cuddapah; Brenda S DiBoscio; James C DiPerna; Patricia L Gordon; Nadene Henderson; Caitlin Menello; Nicole Luongo; Damara Ortiz; Rui Xiao
Journal:  Int J Neonatal Screen       Date:  2020-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.